Hassan Sibai

Dr. Hassan Sibai

Princess Margaret Cancer Centre
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
HSHassan Sibai
Hassan Sibai
RCRuiqi Chen
Ruiqi Chen
XLXing Liu
Xing Liu
UFUmberto Falcone
Umberto Falcone
ASAaron Schimmer
Aaron Schimmer
JSJack T. Seki
Jack T. Seki

1 January 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
MGMark Gower
Mark Gower
XLXiming Li
Ximing Li
AAAlicia G. Aguilar-Navarro
Alicia G. Aguilar-Navarro
BLBrian Lin
Brian Lin
MFMinerva Fernandez
Minerva Fernandez
ATAnastasia N. Tikhonova
Anastasia N. Tikhonova
T-lineage acute lymphoblastic leukemia (ALL) is an aggressive cancer comprising diverse subtypes that are challenging to stratify using conventional immunophenotyping. To gain insights into subset-specific therapeutic vulnerabilities, we performed an integrative multiomics analysis of bone marrow samples from newly diagnosed T cell ALL, early T cell precursor ALL, and T/myeloid mixed phenotype acute leukemia. Leveraging cellular indexing of transcriptomes and epitopes in conjunction with T cell receptor sequencing, we identified a subset of patient samples characterized by activation of inflammatory and stem gene programs. These inflammatory T-lineage samples exhibited distinct biological features compared with other T-lineage ALL samples, including the production of proinflammatory cytokines, prevalence of mutations affecting cytokine signaling and chromatin remodeling, an altered immune microenvironment, and poor treatment responses. Moreover, we found that, although inflammatory T-lineage ALL samples were less sensitive to dexamethasone, they exhibited unique sensitivity to a BCL-2 inhibitor, venetoclax. To facilitate classification of patients with T-lineage ALL, we developed a computational inflammatory gene signature scoring system, which stratified patients and was associated with disease prognosis in three additional patient cohorts. By identifying a high-risk T-lineage ALL subtype on the basis of an inflammatory score, our study provides a framework for targeted therapeutic approaches for these challenging-to-treat cancers.

3 January 2024 in Intensive Care Medicine
Verified
Journal Article
Closed access
PDF file
FCFederico C. Carini
Federico C. Carini
FAFederico Angriman
Federico Angriman
DSDamon C. Scales
Damon C. Scales
LMLaveena Munshi
Laveena Munshi
LBLisa D. Burry
Lisa D. Burry
TGthe SELECTION study group
the SELECTION study group

1 May 2021 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
PPPakpoom Phoompoung
Pakpoom Phoompoung
BHBenoît Henry
Benoît Henry
GDGeorgina Daher-Reyes
Georgina Daher-Reyes
HSHassan Sibai
Hassan Sibai
SHShahid Husain
Shahid Husain

3 August 2022 in eJHaem
Verified
Journal Article
Open access
JSJad Sibai
Jad Sibai
RCRuiQi Chen
RuiQi Chen
INIbrahim Al Nabhani
Ibrahim Al Nabhani
MPMaria Agustina Perusini
Maria Agustina Perusini
HSHassan Sibai
Hassan Sibai
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123-directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we report an 81-year-old female diagnosed with BPDCN. The patient was treated with Tagraxofusp and underwent a remarkably long remission (>20 months) without stem-cell transplantation. She, however, experienced blue toe syndrome and left foot gangrene. We postulate that these previously unreported side effects were caused by microembolization. Characterization of the incidence of thrombo- and microembolizations in such a context, as well as prophylactic management options, are warranted.

16 September 2022 in Genetics in Medicine
Verified
Journal Article
Open access
SASafa Ansar
Safa Ansar
JMJanet Malcolmson
Janet Malcolmson
KFKirsten M. Farncombe
Kirsten M. Farncombe
KYKaren Yee
Karen Yee
RKRaymond Kim
Raymond Kim
HSHassan Sibai
Hassan Sibai
As research on hereditary hematologic malignancy syndromes (HHMS) are accumulating, cancer genetics clinics are identifying more adult hematology patients with an inherited component to their disease. However, investigations for HHMS are complex, and there is no formal consensus on genetic testing criteria. We developed genetic testing criteria for adult hematology patients through a comprehensive literature review and our experience at the Princess Margaret Cancer Centre. We validated our criteria by applying them retrospectively to patients referred to our clinic for HHMS assessment. Our genetic testing criteria are comprehensive of myeloid malignancies, lymphoid malignancies, and bone marrow failure, including age at diagnosis, family history, and genetic test results in blood and bone marrow. Of the 104 patients who met the criteria, 26% had at least 1 actionable variant in any gene associated with an increased risk of cancer and 13% had an actionable variant resulting in an HHMS diagnosis. A total of 15 patients had incidental findings, including 11 patients with a pathogenic variant associated with carrier status for an autosomal recessive disorder and 4 patients with a mosaic result. Our high gene positivity rate shows the utility of a broad approach to germline testing in an adult hematology population.